Navigation Links
Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds

NEW YORK, April 20, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Gastric Cancer Drug Discoveries: what the future holds what-the-future-holds .html

Original analysis of the clinical potential and commercial prospects for companies, launched products and pipeline candidates put into current market context

Original analysis of the clinical potential and commercial prospects for companies, launched products and pipeline candidates put into current market context.

The market is set for rapid and significant growth

There is room for considerable change in the gastric cancer market as improved therapies seek to improve patient outcomes for advanced disease. Over the next seven years, Espicom expects to see the market grow by 133% from US$846 million in 2010, to US$1.97 billion in 2017, with the targeted therapies accounting for most of this growth. While competition amongst these targeted therapies will intensify from 2013/4, Roche will continue to dominate this market with Herceptin, which was recently approved in Japan.

Next generation chemotherapy

While targeted therapies are expected to grow rapidly, it is chemotherapy agents which are leading the current market. One notable success of recent years is Roche's Xeloda, which is replacing 5-FU in the US and EU, where it has been approved as a first-line treatment in gastric cancer since March 2007. With US patents in force until 2013, Xeloda is the only branded chemotherapeutic for gastric cancer not facing generic competition at present.

The rise of targeted therapies

Espicom believes that by 2017, targeted therapies will account for over 60% of the gastric cancer market. Competition for Herceptin will initially come from GSK's Tykerb/Tyverb, but Roche's Avastin, Merck's Erbitux and Lilly's ramucirumab are just some of those waiting in the wings over the coming period. One of the most promising candidates is Bayer's Nexavar where very promising PII trial results have given optimism for its prospects.

More Information...

Critical Business Insights from this report which...

Provides independent, reliable 7-year forecasts, market share and unique product scoring which give you real insights to the current and future business landscape

Evaluates the competitive environment – assess winners and losers and know their pipeline content and status

Covers major launched products and significant pipeline candidates

Identifies promising mid-stage development candidates

Forecasts the launch timeframe for new products or indications

Summarises current clinical thinking on gastric cancer


List of Charts.v

Executive Summary.1

Market Analysis.2

Current Market.2

Next-Generation Chemotherapy.2

Targeted Therapy3

Future Market.4

Sales Forecasts.7

Competitive Analysis8

Competitor Ratio Analysis10

Research and Development12

VEGF Pathway Inhibitors 13

EGFr Inhibitors. 13

Other Targeted Therapies of Interest 14

Chemotherapy. 15

Background Information16

What is Gastric Cancer?.16

The Stages of Gastric Cancer .16

Survival Rates.17

Risk Factors for Gastric Cancer.17

Preventing Gastric Cancer18

Current Treatments.18



Radiation Therapy.19

Why are New Treatments Needed?19

Patient Statistics.19

Gastric Cancer Products.20

Targeted Therapies .22

Approved Products.22


Phase III Products.31






Phase II Products74

AMG 10274

AMG 38676

ARQ 197.79








Gastric Cancer Drug Discoveries

TSU-68 109


Phase I Products.118





Recentin .118



Approved Products.119



Xeloda. 136

Phase II Products. 145

Alimta. 145

Ixempra 150

Tesetaxel 154


Phase Transition Probability. 157

Source Material. 158

List of Tables

The Potential Launch Landscape for Gastric Cancer.4

Gastric Cancer Sales Forecasts (2010-2017).7

Competitor Ratio Analysis Scores.10

Drugs in Clinical Development for Gastric Cancer 12

TNM Stage Grouping16

Five-year Gastric Cancer Survival Rates (US) 17

Targeted Therapies for Gastric Cancer20

Chemotherapy for Gastric Cancer.21

Herceptin Sales by Company (2009-2017).30

Herceptin Sales by Indication (2009-2017).30

Afinitor Sales by Indication (2009-2017).37

Avastin Sales by Company (2009-2017)50

Avastin Sales by Indication (2009-2017).50

Erbitux Sales by Company (2009-2017)60

Erbitux Sales by Indication (2009-2017)61

Ramucirumab Sales by Indication (2014-2017)65

Tykerb/Tyverb Sales by Indication (2009-2017).72

Studies in Metastatic CRC with EGFr-Targeting Monoclonal Antibodies in Irinotecan-Refractory Patients98

Safety Profiles of Leading Anti-EGFr Products and Nimotuzumab99

Efficacy of Docetaxel in the Treatment of NSCLC Patients Previously Treated with a Platinum-Based CT Regimen (Intent-to-Treat Analysis)

Taxotere Sales by Indication (2009-2017)130

S-1 Sales (2009-2017) 135

Xeloda Sales by Company (2009-2017). 143

Xeloda Sales by Indication (2009-2017). 143

Probability of Launch. 157

List of Charts

Gastric Cancer Sales by Therapy (2010)2

Market Share by Product (2010)4

Market Share of Gastric Cancer Therapies (2010)5

Market Share of Gastric Cancer Therapies (2017).5

Market Share by Product (2017)6

Major Players in Gastric Cancer by Market Share (2010).8

Major Players in Gastric Cancer by Market Share (2017).9

Competitor Ratio Analysis Scores. 11

HER2 Signalling Pathway22

Herceptin Sales (2009-2017)30

Afinitor Mode of Action 31

Afinitor Sales (2009-2017).37

Avastin Mode of Action38

Avastin Sales by Company (2009-2017)49

Avastin Sales by Indication, 2010.52

Avastin Sales by Indication, 2017.52

Erbitux Sales (2009-2017)60

Ramucirumab Sales (2014-2017)65

Tykerb/Tyverb Total Sales (2009-2017)72

Tykerb Sales by Indication, 201773

AUY922 Mode of Action Within a Cancer Cell.83

Nexavar's Dual Mode of Action89

Schematic of EGFr Inhibition in Tumourigenesis.111

TAX 317 Survival K_M Curves - Docetaxel 75mg/m2 vs Best Supportive Care 123

TAX 320 Survival K_M Curves - Docetaxel 75mg/m2 vs Vinorelbine or Ifosfamide Control. 124

Taxotere Sales (2009-2017) 129

Taxotere Sales by Indication (2010).130

Taxotere Sales by Indication (2017) 131

S-1 Sales (2009-2017). 134

Xeloda Sales (2009-2017) 142

Xeloda Sales by Indication (2010) 143

Xeloda Sales by Indication (2017)144

To order this report:

: Gastric Cancer Drug Discoveries: what the future holds

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
(Date:10/13/2015)... ) has ... European markets for Meniscal Repair - 16 Countries ... ) has announced the addition of ... Repair - 16 Countries (2010-2021)" report to ... ( ) has announced the addition of ...
(Date:10/13/2015)... , Oct. 13, 2015   Vigilant Biosciences, Inc. ... that aid in the early detection and intervention of ... Vigilant,s founder and CEO, Matthew H.J. Kim , ... which recognizes an entrepreneur who has made extraordinary contributions ... life sciences industry in the leadership of a company ...
(Date:10/13/2015)... , Oct. 13, 2015  EndoChoice Holdings, Inc. ... third quarter 2015 financial results on Thursday, November 5, ... . --> . ... Thursday, November 5, 2015 at 9:00 a.m. ET to ... for domestic callers and (412) 317-5469 for international callers. ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... (PRWEB) October 13, 2015 ... its 2015 annual meeting and corresponding events Oct. 29-31 in ... seminars; a luncheon featuring keynote speaker Air Force Gen. Paul ... the Community Heroes Award Night, which recognizes individuals and groups ...
(Date:10/13/2015)... , ... October 13, 2015 , ... Vision Group Holdings, ... of San Diego, California. With brands including The LASIK Vision Institute and TLC Laser ... it the nationwide leader in laser vision correction. , Global Laser Vision will continue ...
(Date:10/13/2015)... Nashville, Tennessee (PRWEB) , ... October 13, 2015 ... ... owned leader of anesthesia and pain management services, today announced its partnership with ... the partnership integrates data from disparate systems and organizes the data into an ...
(Date:10/13/2015)... ... October 13, 2015 , ... Symposium Chairman, Dr. Rod J. Rohrich ... Cosmetic Symposium to be held March 2nd and 3rd, 2016. The annual meeting, along ... surgeons and cosmetic physicians from around the world. , Key topics at this year's ...
(Date:10/13/2015)... ST. LOUIS and CHENNAI, India (PRWEB) , ... October 13, 2015 ... ... the development of advanced camera solutions, today announced See3CAM_CU40, the industry’s first ... stand-alone MIPI CSI-2 module. See3CAM_CU40, a new member of e-con’s See3CAM family of UVC ...
Breaking Medicine News(10 mins):